December finally had it first IPO, the much-delayed micro-cap diamond maker Adamas One (JEWL) priced at the low end. Coming into year-end there may be small deals on the calendar, but larger IPO will be for next year. E-bike maker SONDORS (SODR) may price in the week ahead, planning to raise $23 million at a $146 million market cap. There is talk, after pushing back the last three weeks BullFrog AI Holdings (BFAI) will price its IPO to raise $8 million. Nano-cap ParaZero … Continue reading “US Weekly IPO and SPAC Monitor: E-Bike Maker SONDORS and Drone Tech ParaZero”
US Weekly IPO and SPAC Monitor: Little Pipeline Activity with BullFrog AI Back on Deck
November ended with a whimper for IPOs as the small deals on the calendar again pushed back their offering plans. There is talk, after pushing back the last two weeks BullFrog AI Holdings (BFAI) will price its IPO to raise $8 million. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors with the stock market surge this week. There are several … Continue reading “US Weekly IPO and SPAC Monitor: Little Pipeline Activity with BullFrog AI Back on Deck”
US Weekly IPO and SPAC Monitor: Lab-grown Diamond Producer Adamas One and BullFrog AI
No IPO’s priced during Thanksgiving week, though the one small deal scheduled to price, lab-grown diamond producer Adamas One (JEWL) may price this week, planning to raise $34 million. BullFrog AI Holdings (BFAI) also plans to raise $8 million. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors with the stock market surge this week. There are several large issuers in the pipeline. … Continue reading “US Weekly IPO and SPAC Monitor: Lab-grown Diamond Producer Adamas One and BullFrog AI”
US Weekly IPO and SPAC Monitor: Lab-grown Diamond Producer Adamas One
There is just one small deal scheduled to price, lab-grown diamond producer Adamas One (JEWL) in the short Thanksgiving week. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors with the stock market surge this week. There are several large issuers in the pipeline, as well as sizable new filings from insurer Skyward Specialty (SKWD) and oil and gas companies TXO Energy Partners (TXO) and BKV Corp (BKV), … Continue reading “US Weekly IPO and SPAC Monitor: Lab-grown Diamond Producer Adamas One”
US Weekly IPO and SPAC Monitor: BullFrog AI and Acrivon Therapeutics
There is just one small deal scheduled to price, Nano-cap BullFrog AI Holdings (BFAI) is developing an analytical AI/ML platform for drug development. Precision oncology biotech Acrivon Therapeutics (ACRV) may also price, after delaying its $100 million IPO. Last week we were surprised by holdover IPOs and one, Intensity Therapeutics (INTS) postponed. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors with the … Continue reading “US Weekly IPO and SPAC Monitor: BullFrog AI and Acrivon Therapeutics”
US Weekly IPO and SPAC Monitor: Biotech Acrivon Therapeutics and Online Games Developer Snail
There are two deals due to price in the week ahead, Precision oncology biotech Acrivon Therapeutics (ACRV) plans to raise $100 million and holdover Intensity Therapeutics (INTS) plans to raise $10 million Online games developer Snail is also expected to Price. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors. The dismal IPO market continued with no new IPO pricings last week in fact … Continue reading “US Weekly IPO and SPAC Monitor: Biotech Acrivon Therapeutics and Online Games Developer Snail”
US Weekly IPO and SPAC Monitor: Following Mobileye’s Strong Debut Watch for Refreshed Filings
Following the strong debut of the Intel Mobileye IPO there are no confirmed IPOs scheduled for the week ahead but some shuffling of papers for a number of micro-caps on the calendar looking to price on a “day-to-day” basis. Often run ups in the stock market as we have seen in the past week bring a few out as brokers look to shift deals in the pipeline to investors. A feature of the IPO market this year is the many … Continue reading “US Weekly IPO and SPAC Monitor: Following Mobileye’s Strong Debut Watch for Refreshed Filings”
US Weekly IPO and SPAC Monitor: Intel’s Mobileye, Biotech’s ASP Isotopes and Intensity Therapeutics
A feature of the IPO market this year is the many names coming up for pricing and being delayed. No surprise with 87% issued in the last year down according to Dealogic. We have the Intel Mobileye IPO listing this week. MBLY is only floating 5% of its basic shares outstanding, well below the typical 15% after the market took to INTC last week. Two holdovers are also expected to debut in the week ahead. Isotope enrichment company ASP Isotopes … Continue reading “US Weekly IPO and SPAC Monitor: Intel’s Mobileye, Biotech’s ASP Isotopes and Intensity Therapeutics”
US Weekly IPO and SPAC Monitor: Gene editing Biotech Prime Medicine and Molybdenum Enricher Aerodynamic Separation Process
We are seeing a little activity in IPO land. A few deals are scheduled to price in the week ahead, and many still on the back burner. Gene editing biotech Prime Medicine (PRME) would be the first sizable IPO of the fourth quarter. Aerodynamic Separation Process (ASP) focusing on the commercialization of enriched Molybdenum-100 plans to list. Three holdovers from the past week are scheduled to price; Beamr Imaging (BMR), Intensity Therapeutics (INTS) and Alopexx (ALPX). Intel’s Mobileye (MBLY) will … Continue reading “US Weekly IPO and SPAC Monitor: Gene editing Biotech Prime Medicine and Molybdenum Enricher Aerodynamic Separation Process”
US Weekly IPO and SPAC Monitor: Biotech Alopexx, Software Companies Beamr and Castellum
The IPO drought continues to worsen along with global liquidity. Fund managers, investors and deal makers are obviously reluctant to wade into new IPOs. On the agenda is Beamr (BMR), an Israeli video encoding and image optimization software provider, OTC-listed intelligence analysis, software development company Castellum (CTM) and infectious disease biotech Alopexx (ALPX). The fourth quarter started off quietly week with just one SPAC priced and three small issuers submitted initial filings. A new SPAC plans to target the new … Continue reading “US Weekly IPO and SPAC Monitor: Biotech Alopexx, Software Companies Beamr and Castellum”